Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
Senti Biosciences’ Business Combination with Dynamics Special Purpose Corp.
Qilu Pharmaceutical’s Licensing Agreement and Partnership with Arbutus Biopharma Corporation
Goodwin Procter advised Qilu Pharmaceutical on the deal. Qilu Pharmaceutical, one of the leading pharmaceutical companies in China (“Qilu”), announced its exclusive licensing agreement and strategic partnership...
Garuda Therapeutics’ Launch and $72 Million Series A Financing
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Intellia Therapeutics’ $690 Million Underwritten Public Offering
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
BridgeBio Pharma’s $2.45 Billion Collaboration and Licensing Agreement with Helsinn Group
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
AbSci’s $125 Million Crossover Financing
Goodwin Procter LLP advised AbSci on the deal. AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The...
MannKind Corporation’s $230 Million Notes Offering
Goodwin Procter LLP advised the initial purchasers on the deal. MannKind Corporation (the “Company”) completed its previously announced private offering (the “Offering”) of $200.0 million aggregate...